November 14th 2024
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Pembrolizumab Granted Breakthrough Therapy Designation in NSCLC
October 27th 2014The FDA has granted a breakthrough therapy designation to pembrolizumab for the treatment of patients with NSCLC who are EGFR mutation- or ALK rearrangement-negative and whose disease has progressed on or following platinum-based chemotherapy.
Read More
Nivolumab Combinations to be Explored in NSCLC
October 7th 2014Several clinical trials combining nivolumab (Opdivo) with targeted therapies against ALK, c-MET, and T790M for patients with non-small cell lung cancer (NSCLC) have been established as part of a collaboration between Novartis and Bristol-Myers Squibb (BMS).
Read More
Resistance in Melanoma May Be Addressed With MAPK Inhibitors and Immunotherapies
September 18th 2014Of the many signaling cascades being targeted for therapeutic intervention in cancer, one of the most important and best understood is the MAPK pathway, particularly the RAS/RAF/MEK/ERK cascade.
Read More
Challenges Apparent With Current Targeted Therapies for BRAF Metastatic Melanoma
September 18th 2014Several advances in the treatment of metastatic melanoma have occurred in the last 5 years, one of which has been the approval by the FDA of targeted treatments for patients with melanomas harboring a BRAF mutation.
Read More
Low-Risk Stage IV NSCLC Patients Achieve Long-Term Survival After Aggressive Treatment
September 17th 2014Timing of metastatic development, lymph node involvement, and type of disease all factor into the overall survival (OS) rate of patients with stage IV NSCLC, and could offer a potential risk stratification scheme for ablative therapy.
Read More
The Potential Benefit for a Blood-Based Test to Detect a T790M Mutation
September 9th 2014Paul A. Bunn, Jr., MD, Giant of Cancer Care: Lung Cancer, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, discusses the potential benefit for a blood-based test to detect a T790M mutation in lung cancer.
Watch
Evolving Survival Rates in Non-Small Cell Lung Cancer
August 30th 2014Lung cancer remains the leading cause of cancer-related mortality in the United States, despite decreases in lung cancer mortality rates beginning in 1991 for the male population and decreases beginning in 2003 for female population.
Read More
Early-Stage Lung Cancer: Refining Treatment Plans
August 26th 2014The optimal management of patients with early-stage NSCLC remains controversial, and the prospect of exposing an otherwise low-risk patient to potentially toxic chemotherapy based on limited prognostic information remains a problem for many clinicians.
Read More
AstraZeneca Partners With QIAGEN, Roche to Develop Companion Diagnostics for Lung Cancer Drugs
August 11th 2014AstraZeneca has announced new collaborations with QIAGEN and Roche to create 2 separate, noninvasive companion diagnostic tests to be used with 2 of its drugs for NSCLC, gefitinib (IRESSA) and AZD9291.
Read More